Taking peoplePhase 1
A Clinical Study of Cizutamig in Thyroid Eye Disease
Key facts
- Who runs it
- Candid Therapeutics
- Where
- China14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 38 people, planned
- Started
- 8 May 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Treatments tested
- Cizutamig will be dosed according to the protocol.
- Record updated
- 1 September 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 18-75 years old at the time of signing the Informed Consent Form
- Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1
Who cannot take part
- Receipt of, or inability to discontinue, any of the excluded therapies
- Active infection present
- History of progressive multifocal leukoencephalopathy
- History of primary immunodeficiency
- Central nervous system disorders that the investigator considers would increase risk to the subject
- Have a diagnosis or history of malignant disease within 5 years prior to Screening
- Active tuberculosis or lack of documentation of completed treatment for active pulmonary tuberculosis
- History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of cizutamig
- Inadequate clinical laboratory parameters at Screening
- Investigator-determined significant comorbidity(ies)
- Pregnant or breastfeeding women
- Patients who do not agree to use highly effective contraception as specified in the protocol
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).
The group in the trial
- CizutamigTreatment being tested
Treatment: Cizutamig will be dosed according to the protocol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Thyroid Eye Disease
- Fit questions
- Built from NCT07597200, who can take part
- Record updated
- 1 September 2026